» Articles » PMID: 20570136

Socioeconomic Status and Changing Inequalities in Colorectal Cancer? A Review of the Associations with Risk, Treatment and Outcome

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2010 Jun 24
PMID 20570136
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Upcoming mass screening for colorectal cancer (CRC) makes a review of recent literature on the association with socioeconomic status (SES) relevant, because of marked and contradictory associations with risk, treatment and outcome.

Methods: The Pubmed database using the MeSH terms 'Neoplasms' or 'Colorectal Neoplasms' and 'Socioeconomic Factors' for articles added between 1995 and 1st October 2009 led to 62 articles.

Results: Low SES groups exhibited a higher incidence compared with high SES groups in the US and Canada (range risk ratio (RR) 1.0-1.5), but mostly lower in Europe (RR 0.3-0.9). Treatment, survival and mortality all showed less favourable results for people with a lower socioeconomic status: Patients with a low SES received less often (neo)adjuvant therapy (RR ranging from 0.4 to 0.99), had worse survival rates (hazard ratio (HR) 1.3-1.8) and exhibited generally the highest mortality rates up to 1.6 for colon cancer in Europe and up to 3.1 for rectal cancer.

Conclusions: A quite consistent trend was observed favouring individuals with a high SES compared to those with a low SES that still remains in terms of treatment, survival and thus also mortality. We did not find evidence that the low/high SES gradients for treatment chosen and outcome are decreasing. To meet increasing inequalities in mortality from CRC in Europe for people with a low SES and to make mass screening successful, a high participation rate needs to be realised of low SES people in the soon starting screening program.

Citing Articles

Global, regional, and national burden of colorectal cancer, 19902021: An analysis from global burden of disease study 2021.

Wang J, He S, Cao M, Teng Y, Li Q, Tan N Chin J Cancer Res. 2025; 36(6):752-767.

PMID: 39802900 PMC: 11724172. DOI: 10.21147/j.issn.1000-9604.2024.06.12.


Species-level verification of association with colorectal cancer.

Bucher-Johannessen C, Senthakumaran T, Avershina E, Birkeland E, Hoff G, Bemanian V mSystems. 2024; 9(10):e0073424.

PMID: 39287376 PMC: 11494908. DOI: 10.1128/msystems.00734-24.


Global, regional, and national analyses of the burden of colorectal cancer attributable to diet low in milk from 1990 to 2019: longitudinal observational study.

Zhang X, Zhang X, Li R, Lin M, Ou T, Zhou H Front Nutr. 2024; 11:1431962.

PMID: 39104758 PMC: 11299434. DOI: 10.3389/fnut.2024.1431962.


Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014-2017 and Projected Rates to 2025.

AziziKia H, Teymourzadeh A, Kouchaki H, Nakhostin-Ansari A, Jafari Doudaran P, Ahmadinejad I Arch Iran Med. 2024; 27(4):174-182.

PMID: 38685843 PMC: 11097305. DOI: 10.34172/aim.2024.26.


Perceived Economic Strain, Subjective Social Status, and Colorectal Cancer Screening Utilization in U.S. Men-A Cross-Sectional Analysis.

Korous K, Brooks E, King-Mullins E, Lucas T, Tuuhetaufa F, Rogers C Behav Med. 2024; 51(1):51-60.

PMID: 38618978 PMC: 11473714. DOI: 10.1080/08964289.2024.2335156.